| http://identifiers.org/pubm... | rdf:type | biopax3:PublicationXref | lld:biopax3 |
| http://identifiers.org/pubm... | biopax3:author | Meeus, P | lld:biopax3 |
| http://identifiers.org/pubm... | biopax3:author | Vandenberghe, P | lld:biopax3 |
| http://identifiers.org/pubm... | biopax3:author | Lierman, E | lld:biopax3 |
| http://identifiers.org/pubm... | biopax3:author | Wasag, B | lld:biopax3 |
| http://identifiers.org/pubm... | biopax3:author | Cools, J | lld:biopax3 |
| http://identifiers.org/pubm... | biopax3:db | PubMed | lld:biopax3 |
| http://identifiers.org/pubm... | biopax3:id | 21330321 | lld:biopax3 |
| http://identifiers.org/pubm... | biopax3:source | Haematologica 96:922-6 | lld:biopax3 |
| http://identifiers.org/pubm... | biopax3:title | The kinase inhibitor TKI258 is active against the novel CUX1-FGFR1 fusion detected in a patient with T-lymphoblastic leukemia/lymphoma and t(7;8)(q22;p11) | lld:biopax3 |
| http://identifiers.org/pubm... | biopax3:year | 2011 | lld:biopax3 |
| http://www.reactome.org/bio... | biopax3:xref | http://identifiers.org/pubm... | lld:biopax3 |
| http://www.reactome.org/bio... | biopax3:xref | http://identifiers.org/pubm... | lld:biopax3 |
| http://www.reactome.org/bio... | biopax3:xref | http://identifiers.org/pubm... | lld:biopax3 |
| http://www.reactome.org/bio... | biopax3:xref | http://identifiers.org/pubm... | lld:biopax3 |
| http://www.reactome.org/bio... | biopax3:xref | http://identifiers.org/pubm... | lld:biopax3 |
| http://www.reactome.org/bio... | biopax3:xref | http://identifiers.org/pubm... | lld:biopax3 |
| http://www.reactome.org/bio... | biopax3:xref | http://identifiers.org/pubm... | lld:biopax3 |
| http://www.reactome.org/bio... | biopax3:xref | http://identifiers.org/pubm... | lld:biopax3 |
